Education
About Us
Working with TipRanks
Follow Us
Assembly Biosciences (ASMB)
NASDAQ:ASMB
ASMB Stock Chart & Stats
$27.66
-$0.45(-2.59%)
At close: 4:00 PM EST
$27.66
-$0.45(-2.59%)
Day’s Range― - ―
52-Week Range$7.75 - $39.71
Previous CloseN/A
Volume7.37K
Average Volume (3M)164.41K
Market Cap
$437.50M
Enterprise Value$417.80M
Total Cash (Recent Filing)$232.56M
Total Debt (Recent Filing)$2.75M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,817,140
10 Day Avg. Volume178,321
30 Day Avg. Volume164,409
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.84
Price to Sales (P/S)3.32
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue11.23
Enterprise Value/Gross Profit61.57
Enterprise Value/Ebitda-10.04
Forecast
1Y Price Target
$44.50Price Target Upside60.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.04
Revenue Forecast (FY)$21.80M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy DifferentiationPhase 1b results showing sustained HSV-2 shedding reductions for ABI-1179 and ABI-5366 reinforce the helicase-primase inhibitor class as a potentially best-in-class oral option with superior efficacy and dosing convenience.
Development Timeline And RunwayClear progression plans with ABI-5366 expected to enter Phase 2 in mid-2026 and a cash runway into late 2027 give a funded path to advance the antiviral portfolio and pursue later-stage studies.
Partnership And FundingGilead's opt-in and milestone arrangement provides non-dilutive upfront funding and aligned partner support to advance combined HSV programs toward late-stage development.
Bears Say
Dilution RiskRequirement for additional capital to fund development and commercialization could lead to equity dilution that diminishes per-share value for existing investors.
Manufacturing And Regulatory DelaysManufacturing scale-up requirements and potential regulatory review delays could postpone trial progression or product launches, increasing costs and timeline uncertainty.
Partner Concentration RiskDependence on a single major partner for program advancement concentrates strategic risk and could limit flexibility if partner priorities or decisions change.
Assembly Biosciences News
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $7.75 and its highest was $39.70 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $437.50M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is May 07, 2026 which is in 61 days.
How were Assembly Biosciences’s earnings last quarter?
Currently, no data Available
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 15,817,140 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$44.50 (60.88% Upside)
$44.50 (60.88% Upside)
Hedge Fund Trend
Decreased
By 129.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.70%
12-Months-Change
Fundamentals
Return on Equity
-36.94%
Trailing 12-Months
Asset Growth
-29.95%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
ASMB Stock 12 Month Forecast
Average Price Target
$44.50
▲(60.88% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---